LWLihua Wu

Lihua Wu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lihua Wu has a total of 42 co-authors. Here are the top co-authors by number of shared publications:

  • Jianzhong Shentu

    Research Center of Clinical Pharmacy, State Key Laboratory for Diagnosis and Treatment of Infectious Disease, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China

    6 shared publications
  • Meihua Lin

    Zhejiang Univ, Affiliated Hosp 1, Res Ctr Clin Pharm, Zhejiang Prov Key Lab Drug Evaluat & Clin Res,Coll, Hangzhou, Zhejiang, Peoples R China

    6 shared publications
  • You Zhai

    Zhejiang Univ, Affiliated Hosp 1, Res Ctr Clin Pharm, Zhejiang Prov Key Lab Drug Evaluat & Clin Res,Coll, Hangzhou, Zhejiang, Peoples R China

    6 shared publications
  • Yunliang Zheng

    Research Center of Clinical Pharmacy, State Key Laboratory for Diagnosis and Treatment of Infectious Disease, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China

    6 shared publications
  • Duo Lv

    Research Center of Clinical Pharmacy, State Key Laboratory for Diagnosis and Treatment of Infectious Disease, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China

    4 shared publications
  • Jian Liu

    Zhejiang Univ, Affiliated Hosp 1, Res Ctr Clin Pharm, Zhejiang Prov Key Lab Drug Evaluat & Clin Res,Coll, Hangzhou, Zhejiang, Peoples R China

    4 shared publications

Latest Publications

  • Bioequivalence study of domperidone dry suspension in healthy Chinese subjects under fasted and fed conditions: An open-label, randomized, single-dose, crossover trial

    by Lihua Wu, Qian Huang, Meihua Lin, Jiejing Kai, Yujie Huang, You Zhai, Jian Liu, Jianzhong Shentu

    Background: Domperidone has long been used as a prokinetic agent in the treatment of epigastric distress symptoms. This study aimed to provide adequate evidence for registration approval of a new generic dry suspension formulation of domperidone by comparing the safety and pharmacokinetic profiles between the test and branded reference formulation in the context of fasted and fed condition. Materials and methods: This was designed as a randomized, open-label, single-dose, two period, two-treatment crossover study. 32 and 28 eligible healthy subjects were enrolled in the fasted and fed study, respectively. Each subject was randomly assigned to receive either the test or reference formulation in the first period, followed by a 1-week washout period and dosing of the alternate formulation in the second period. A series of blood samples were collected at scheduled timepoints within 48 hours after administration during each treatment period. Plasma concentrations of domperidone were determined by validated HPLC-MS/ MS. Pharmacokinetic parameters, including Cmax, tmax, AUC0-t, AUC0-infinity, and T1/2, were acquired based on the concentration vs. time profiles by non-compartmental analysis using WinNonlin software. Then the geometric mean ratios (GMR) of Cmax, AUC0-t, and AUC0-infinity between the two formulations and corresponding 90% confidence intervals (CIs) were calculated for bioequivalence determination. Safety was assessed as routine. Results: The two formulations showed similar pharmacokinetic profiles. Under fasted condition, the GMR and corresponding 90% CIs of AUC0-t, AUC0-infinity, and Cmax were 101.48% (96.79 - 106.38%), 101.17% (96.66 - 105.90%), and 104.61% (96.73 - 113.14%), respectively. Under fed condition, the GMR and corresponding 90% CIs were 105.46% (99.19 - 112.12%), 104.21% (98.19 - 110.61%), and 112.78% (103.64 - 122.73%), respectively, for AUC0-t, AUC0-infinity, and Cmax. All values fell within the accepted bioequivalence range of 80 - 125%. Both the test and the reference products were well tolerated without any serious or unexpected adverse reactions. Conclusion: Pharmacokinetic bioequivalence was established between the two dry suspension formulations of domperidone in healthy Chinese subjects. Both products were safe and well tolerated.

  • Open Access

    Bioequivalence Study of Domperidone Dry Suspension in Chinese Healthy Subjects Under Fasted and Fed Conditions: An Open-label, Randomized, Single-dose, Crossover Trial

    by Lihua Wu, Qian Huang, Meihua Lin, Jiejing Kai, Yujie Huang, You Zhai, Jian Liu, Jianzhong Shentu

    Background Domperidone, a selective antagonist of dopamine D2 receptors, has long been used as a prokinetic agents in the treatment of epigastric distress symptoms. This study aimed to provide adequate evidence for registration approval of a new genetic dry suspension formulation of domperidone by comparing the safety and pharmacokinetic profiles between the test and branded reference formulation in the context of fasted and fed condition.Methods It was designed as a randomized, open-label, single-dose, two-period, two-treatment crossover study. 32 and 28 eligible healthy subjects were enrolled in the fasted and fed study, respectively. Each subject was randomly assigned to receive either the test or reference formulation in the first period, followed by a 1-week washout period and dosing of the alternate formulation in the second period. A series of blood samples were collected at scheduled timepoints within 48 hours after administration during each treatment period. Plasma concentrations of domperidone were determined by validated HPLC-MS/MS. Pharmacokinetic parameters, including Cmax, Tmax, AUC0–t, AUC0–∞, and t1/2, were acquired based on the concentration versus time profiles by non-compartmental analysis using WinNonlin software. Then the geometric mean ratios (GMR) of Cmax, AUC0–t and AUC0–∞ between the two formulations and corresponding 90% confidence intervals (CIs) were calculated for bioequivalence determination. Safety was assessed as routine.Results The two formulations showed similar pharmacokinetic profiles. Under fasted condition, the GMR and corresponding 90% CIs of AUC0–t, AUC0-∞ and Cmax were 101.48% (96.79% to 106.38%), 101.17% (96.66% to 105.90%) and 104.61% (96.73% to 113.14%) , respectively. Under fed condition, the GMR and corresponding 90% CIs were 105.46% (99.19% to 112.12%), 104.21% (98.19% to 110.61%) and 112.78% (103.64% to 122.73%), respectively for AUC0–t, AUC0-∞ and Cmax. All the values fell within the accepted bioequivalence range of 80% to 125%. Both the test and the reference products were well tolerated without any serious or unexpected adverse reactions.Conclusions Pharmacokinetic bioequivalence was established between the two dry suspension formulations of domperidone in Chinese healthy subjects. Both products were safe and well tolerated.Trial Registration ChiCTR, ChiCTR1900023947. Registered 19 June 2019- Retrospectively registered, http:// www.chictr.org.cn/ChiCTR1900023947.

  • The impact of rifampicin on the pharmacokinetics of fuzuloparib in healthy Chinese male volunteers

    by Qiao Zhang, Jiejing Kai, You Zhai, Nana Xu, Jianzhong Shentu, Yanyan Zhang, Yanjuan Liang, Yuya Wang, Lihua Wu

    Aims This clinical study was conducted to evaluate the impact of rifampicin on the pharmacokinetics of fuzuloparib (clinicaltrials.gov, NCT04011124). Methods In this single center, single arm, open label, fixed sequence study, healthy male subjects took a single dose of 50 mg of fuzuloparib at 2 separate occasions: one was on D1 as monotherapy, the other was on D12 after oral administration of rifampicin 600 mg once daily for 8 days. Series of blood samples were obtained before and after fuzuloparib administration at different time points: pre-dose, and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 h post-dose. All samples were detected using liquid chromatography with tandem mass spectrometry method. PK parameters were estimated by using a non-compartmental method with Phoenix WinNonlin software. Safety was assessed by monitoring for changes in vital signs and laboratory tests, physical examinations, and incidences of adverse events (AEs). Results A total of 16 Chinese male subjects were enrolled. 16 and 15 cases were evaluable for PK analysis following administration with fuzuloparib alone and pretreatment with rifampicin, respectively. Pretreatment with rifampicin resulted in a statistically significant reduction in the systemic exposure to fuzuloparib. The treatment ratio and 90% confidence intervals (CIs) for AUC0-∞ and Cmax were 0.10 (0.095-0.115) and 0.32 (0.281-0.365), respectively. A single administration of fuzuloparib after multiple oral dosing of rifampicin was well-tolerated, without severe AEs. Conclusion The exposure of fuzuloparib was dramatically decreased when pretreated with rifampicin. Strong CYP3A4 inducers should be avoided during fuzuloparib treatment.


  • A Metastatic Intrahepatic Cholangiocarcinoma Treated with Programmed Cell Death 1 Inhibitor: A Case Report and Literature Review

    by Jingjing Zhang, Lihua Wu, Jian Liu, Meihua Lin

    Intrahepatic cholangiocarcinoma is a disease with grave prognosis due to limited therapeutic regimens. Programmed cell death 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitor have shown dramatic...


  • Open Access

    Effects of Tenofovir on the Single-Dose Pharmacokinetics of Intravenous Morinidazole in Healthy Chinese Subjects

    by Guolan Wu, Wenling Tang, Duo Lv, Lihua Wu, Huili Zhou, Xi Yang, Yunliang Zheng, You Zhai, Jianzhong Shentu

    The effects of multiple-dose administration of tenofovir disoproxil fumarate (TDF) on the pharmacokinetics of morinidazole (MOR) were compared in healthy subjects. MOR exposure was similar, with an area under the curve from 0 h to infinity (AUC 0-∞ ) treatment ratio for MOR+TDF/MOR of 1.01 (90% confidence interval, 0.97 to 1.06). No relevant differences were observed regarding plasma exposure of metabolites. Renal clearances of MOR and its metabolites were not affected by TDF.


  • Open Access

    Pharmacokinetics and Tolerability of Single and Multiple Intravenous Doses of Cefotetan Disodium in Healthy Chinese Volunteers

    by Jian Liu, You Zhai, Lihua Wu, Guolan Wu, Yunliang Zheng, Xingjiang Hu, Jianzhong Shentu

    Background: Cefotetan is highly stable to penicillinase and cephalosporin produced by gram-negative bacteria, and it has strong antimicrobial activity against most gram-negative bacteria, some anaerobic bacteria and streptococcus. The objective of this study was to evaluate the pharmacokinetic profile and tolerability of single and multiple intravenous doses of cefotetan disodium in healthy Chinese volunteers. Methods: In this single-center, open-label, dose-escalating study, subjects were randomized to receive a single dose of cefotetan disodium 0.5, 1.0, or 2.0 g administered as a 1 h intravenous infusion. After completion of the single-dose phase, subjects continued into the multiple-dose phase, in which they received 1.0 g cefotetan disodium BID for 7 consecutive days. Plasma samples were assayed by a validated high-performance liquid chromatography-tandem mass spectrometry method. Pharmacokinetic parameters were calculated and analyzed statistically. Tolerability was assessed based on physical examinations, vital signs, laboratory tests, and subject interviews. Results: After intravenous administration of single doses of 0.5, 1.0, and 2.0 g cefotetan disodium, the pharmacokinetics of cefotetan were as follows: Cmax was 69.49± 12.10 μg·mL− 1, 132.03± 22.56 μg·mL− 1 and 237.75± 42.12 μg·mL− 1, respectively; AUClast was 278.29± 51.13 μg·mL− 1·h, 543.25± 92.44 μg·mL− 1·h and 1003.8± 172.39 μg·mL− 1·h, respectively; AUC∞ was 284.42± 50.76 μg·mL− 1·h, 551.38± 95.83 μg·mL− 1·h and 1020.18± 181.19 μg·mL− 1·h, respectively; t1/2 was 4.21± 0.83 h, 4.39± 0.53 h and 4.27± 0.74 h, respectively; CL was 1.81± 0.33 L·h− 1, 1.86± 0.32 L·h− 1 and 2.02± 0.38 L·h− 1, respectively; Vd was 10.80± 1.89L, 11.78± 2.20L and 12.25± 1.99L, respectively. In the multiple-dose study, the pharmacokinetics of cefotetan were as follows: Cmax,ss was 147.58± 22.71 μg·mL− 1; Cmin,ss was 12.92± 3.70 μg·mL− 1; Cavg was 45.10± 7.78 μg·mL− 1; AUCτ,ss was 541.15± 93.36 μg·mL− 1·h; AUC∞ was 612.06± 114.23 μg·mL− 1·h; t1/2 was 4.30± 0.63 h; CL was 1.90± 0.35L·h− 1; Vd was 8.91± 1.57L; DF was 300.92± 33.28%; Accumulation Index was 1.17± 0.05. No serious adverse events were reported. Adverse events were generally mild. Conclusion: Cefotetan disodium showed favorable tolerability in this study. The Cmax and AUCs of cefotetan disodium demonstrated dose-dependent pharmacokinetic characteristics after single dose over a dose range (0.5– 2.0 g) in healthy subjects, whereas the t1/2 was independent of dose. Except for Vd, there was no difference in other pharmacokinetic parameters between multiple and single administration.

  • Open Access

    Bioequivalence Study Of A Fixed-Dose Combination Tablet Containing Melitracen 10 mg And Flupentixol 0.5 mg In Healthy Chinese Volunteers Under Fasted And Fed Conditions

    by Lihua Wu, Chang Xu, Guolan Wu, Huili Zhou, Duo Lv, You Zhai, Yujie Huang, Wenling Tang, Fangqiong Li, Jianzhong Shentu

    Purpose: A fixed-dose combination (FDC) tablet of melitracen/flupentixol has been widely used for depression. The purpose of this study was to assess the safety profile and the relative bioavailability of two FDC products containing 10 mg melitracen and 0.5 mg flupentixol from two different manufacturers, in order to acquire adequate pharmacokinetic evidence for registration approval of the test formulation. Methods: The study was designed as a single-dose, randomized, open-label, 2-period crossover study under fasted or fed conditions in healthy Chinese subjects. Twenty-four subjects (16 men and 8 women) were selected for fasted study, and another 24 cases (16 men and 8 women) were in fed study. Each subject was randomized at the beginning to receive either a single dose of the reference FDC or the test FDC tablet during the first period. Following two-week washout period, all subjects received the alternate formulation during the second period. Blood samples were collected up to 144 hrs after administration. Pharmacokinetic parameters, including Cmax, Tmax, AUC0-t, AUC0-∞, t½, CL/F, and Vd/F were acquired based on the time versus concentration profiles. Then, the geometric mean ratios (GMR) and corresponding 90% CIs were calculated for the determination of bioequivalence analysis. Safety assessment included changes in vital signs and laboratory tests, physical examination findings, and incidence or reports of adverse events (AEs). Results: The present study has clearly indicated the test and the reference FDC products are bioequivalent in terms of rate and extent of drug absorption. GMR of Cmax, AUC0–t, and AUC0-∞ for both flupentixol and melitracen between the two formulation FDC products, and corresponding 90% CIs, were all within the range of 80% to 125% under fasted or fed conditions. Both the test and the reference FDC products indicated good tolerance in all volunteers. Chinese Clinical Trials Registry identifier: CTR20171256.


  • Open Access

    Pharmacokinetic/Pharmacodynamic Evaluation of Dexlansoprazole Infusion Injection Compared with Lansoprazole in Healthy Chinese Adults

    by Lihua Wu, Jian Liu, Yunliang Zheng, You Zhai, Meihua Lin, Guolan Wu, Duo Lv, Jianzhong Shentu

    Background and Objective This study was performed in healthy Chinese subjects to evaluate the safety and pharmacokinetic/pharmacodynamic characteristics of a novel injection formulation of dexlansoprazole in the context of single and multiple administration, compared with the original lansoprazole injection. Methods Helicobacter pylori-negative healthy volunteers were recruited, and 70 participants were enrolled into five dosing groups (seven males and seven females in each group), including 15 mg once daily (qd), 15 mg every 12 h (q12h), 30 mg qd and 30 mg q12h of dexlansoprazole treatment for 5 days, as well as 30 mg q12h of lansoprazole treatment for 5 days. Blood samples were collected at scheduled time spots postdose on day 1 (first dose) and day 5 (last dose). Twenty-four-hour intragastric pH was continuously monitored on day 0 (baseline) and days 1 and 5. Dexlansoprazole and S-lansoprazole in human plasma were determined by validated chiral liquid chromatography with tandem mass spectrometry, and the pharmacokinetic parameters were determined by a non-compartmental method using Phoenix WinNonlin software. Safety assessment included changes in vital signs and laboratory tests, physical examination findings, and incidence or reports of adverse events. Results The half-life (t½) and clearance (CL) of dexlansoprazole were 1.76–2.06 h and 4.52–5.40 L/h, respectively, while the t½ and CL of S-lansoprazole were 0.87–1.02 h and 34.66–35.98 L/h, respectively. No drug accumulation after repeated administration was noted. Administration of lansoprazole 30 mg resulted in higher area under the concentration-time curve from time zero to the last measurable concentration (AUCt) of dexlansoprazole than that of dexlansoprazole 15 mg (p = 0.026). Zero to 24 h after q12h multiple dosing, median and mean intragastric pH, percentage of time with the intragastric pH above 4.0 [TpH ≥ 4.0(%)] and percentage of time with the intragastric pH above 6.0 [TpH ≥ 6.0(%)] in the dexlansoprazole 15 mg q12h group were 6.07 ± 0.61, 5.70 ± 0.76, 83.58 ± 12.34, and 53.70 ± 17.06, respectively, which was similar to the lansoprazole 30 mg q12h group, i.e. 6.15 ± 0.62, 5.88 ± 0.67, 87.26 ± 12.08 and 57.00 ± 16.35, respectively. A weak positive correlation between dexlansoprazole AUCt and baseline-adjusted TpH ≥ 4.0(%) over 0–24 h was observed, with Pearson correlation coefficients of 0.437 (p = 0.029), while no correlation was observed between AUCt and baseline-adjusted TpH ≥ 6.0(%) over 0–24 h. Conclusion Every 12 h intravenous dosing of dexlansoprazole up to 30 mg for 5 days was safe and well-tolerated in healthy Chinese subjects. Every 12 h dosing of dexlansoprazole 15 mg has a comparable effect of gastric acid inhibition as lansoprazole 30 mg q12h. Trial Registration ClinicalTrials.gov ID NCT03120273.


  • Open Access

    Downregulation of CPT2 promotes tumorigenesis and chemoresistance to cisplatin in hepatocellular carcinoma

    by Meihua Lin, Duo Lv, Yunliang Zheng, Minglan Wu, Chang Xu, Qiao Zhang, Lihua Wu

    Background: Cancer cells often have characteristic changes in metabolism. Besides Warburg effect, abnormal lipid metabolism is also considered as one of the most typical metabolic symbols of cancer. Thus, understanding the mechanisms of cell metabolic reprogramming may provide a potential avenue for cancer treatment. Materials and methods: In total, 41 pairs of matched samples of primary hepatocellular carcinoma (HCC) and adjacent non-cancerous liver tissues were collected. Afterward, we performed quantitative reverse transcriptase polymerase chain reaction to investigate carnitine palmitoyltransferase-2 (CPT2) expression and then systematically analyzed its relationship with clinicopathologic features. We further performed proliferation, colony formation, migration and invasion, drug resistance, and lipogenesis assays to determine the function of CPT2 in HCC. Results: In this study, we have identified CPT2 which is the rate-limiting enzyme of fatty acid oxidation, downregulated in HCC and was significantly associated with tumor histological differentiation and venous invasion. In vitro studies demonstrated that knockdown of CPT2 remarkably enhanced the tumorigenic activity and metastatic potential of hepatoma cells. In addition, CPT2 silencing induced chemoresistance to cisplatin. Mechanistically, low expression of CPT2 promoted cancer cell lipogenesis via upregulation of stearoyl-CoA desaturase-1, the key enzyme involved in the synthesis of monounsaturated fatty acids, at both mRNA and protein levels in hepatoma cell line. Conclusion: Altogether, our findings demonstrate that CPT2 has a critical role in HCC progression and chemoresistance and may potentially serve as a novel prognostic marker and therapeutic target for HCC treatment.


  • Open Access

    A polymorphism in the tumor suppressor p53 affects aging and longevity in mouse models

    by Yuhan Zhao, Lihua Wu, Xuetian Yue, Cen Zhang, Jianming Wang, Jun Li, Xiaohui Sun, Yiming Zhu, Zhaohui Feng, Wenwei Hu

    Tumor suppressor p53 prevents early death due to cancer development. However, the role of p53 in aging process and longevity has not been well-established. In humans, single nucleotide polymorphism (SNP) with either arginine (R72) or proline (P72) at codon 72 influences p53 activity; the P72 allele has a weaker p53 activity and function in tumor suppression. Here, employing a mouse model with knock-in of human TP53 gene carrying codon 72 SNP, we found that despite increased cancer risk, P72 mice that escape tumor development display a longer lifespan than R72 mice. Further, P72 mice have a delayed development of aging-associated phenotypes compared with R72 mice. Mechanistically, P72 mice can better retain the self-renewal function of stem/progenitor cells compared with R72 mice during aging. This study provides direct genetic evidence demonstrating that p53 codon 72 SNP directly impacts aging and longevity, which supports a role of p53 in regulation of longevity.